BLAINJECTIONINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NEMLUVIO (nemolizumab-ilto) by Galderma is interleukin-31 receptor alpha antagonists [moa]. First approved in 2024.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEMLUVIO (nemolizumab-ilto) is a monoclonal antibody that blocks interleukin-31 receptor alpha, a key driver of pruritus and inflammation in chronic inflammatory skin diseases. It is administered via subcutaneous injection and represents a novel mechanism targeting the IL-31 signaling pathway. The drug addresses severe pruritus in patients with conditions where conventional therapies have proven insufficient.
Growth
Recent approval positions NEMLUVIO in early-stage commercialization with expanding team opportunities across market access, field sales, and commercial strategy functions.
Mechanism of Action
Interleukin-31 Receptor alpha Antagonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEMLUVIO offers career entry and growth opportunities in a newly launched specialty biologic with significant market development potential in dermatology. Professionals joining now will shape the product's early commercial trajectory and expansion strategy across therapeutic areas.
Brand ManagerMedical Science Liaison
Worked on NEMLUVIO at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.